# Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

> **NCT01586195** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01586195
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-31
- **Primary completion:** 2015-04-30
- **Final completion:** 2015-04-30
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Recruitment challenges
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01586195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01586195, "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01586195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*